21-Gene Recurrence Score Index (ONCOTYPE DX) as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2-breast cancer

被引：0
|
作者：
Cudos, Ariadna Gasol
Murillo, Serafin Morales
Der-Abrain, Noemi Tuset
Villellas, Felip Vilardell
Cid, Laura Arbones
Olive, Jordi Mele
Morales, Carles Canosa
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO2-01-10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO2-01-10
引用
收藏
页数：2
相关论文
共 50 条
  • [1] MammaPrint Index as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2-breast cancer in NBRST.
    Beitsch, Peter D.
    Pellicane, James V.
    Pusztai, Lajos
    Baron, Paul
    Cobain, Erin Frances
    Murray, Mary K.
    Ashikari, Andrew
    Kelemen, Pond R.
    Mislowsky, Angela Marie
    Barone, Julie
    Cowan, Kenneth H.
    Rahman, Rakhshanda Layeequr
    Dooley, William C.
    Menicucci, Andrea
    Finn, Christine
    Audeh, M. William William
    Whitworth, Pat W.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Recurrence Score® result by the 21-gene assay before and after systemic neoadjuvant chemotherapy in patients with HR+HER2-breast cancer.
    Ciriaco, N.
    Vieites, B.
    Bellet, M.
    Castilla, C.
    Gomez Pardo, P.
    Perez-Luque, A.
    Lopez, M. A.
    Salvador Bofill, F. J.
    Alfaro, L.
    Perez Garcia, J. M.
    Espinosa-Bravo, M.
    Flannery, C.
    Hagen, C.
    Peg, V.
    BREAST, 2023, 68 : S60 - S60
  • [3] 21-Gene Oncotype DX® Recurrence-Score benefits and application in elderly breast cancer patients
    Chiru, E. D.
    Kuhar, C. Grasic
    Oseledchyk, A.
    Kurzeder, C.
    Vetter, M.
    SWISS MEDICAL WEEKLY, 2022, 152 : 43S - 43S
  • [4] Use of the 21-gene Oncotype DX® Breast Recurrence Score™ (RS) assay in the neoadjuvant treatment setting
    Robidoux, A.
    McCullough, D.
    Lau, A.
    Stoppler, M.
    Chao, C.
    BREAST, 2017, 32 : S80 - S80
  • [5] YAP1 Expression in HR+HER2-Breast Cancer: 21-Gene Recurrence Score Analysis and Public Dataset Validation
    Park, Inho
    Lee, Yangkyu
    Kim, Jee Hung
    Bae, Soong June
    Ahn, Sung Gwe
    Jeong, Joon
    Cha, Yoon Jin
    CANCERS, 2023, 15 (20)
  • [6] Evaluation Oncotype DX® 21-Gene Recurrence Score and clinicopathological parameters in early stage breast cancer
    Lashen, A. L.
    Toss, M. T.
    Fadhil, W. F.
    Oni, G. O.
    Madhusudan, S. M.
    Rakha, E. R.
    JOURNAL OF PATHOLOGY, 2023, 261 : S10 - S10
  • [7] Genetic Ancestry and 21-Gene Oncotype DX Breast Cancer Recurrence Scores
    Borowsky, Peter A.
    Hernandez, Alexandra E.
    Kesmodel, Susan B.
    Goel, Neha
    ANNALS OF SURGICAL ONCOLOGY, 2025,
  • [8] Long-term prediction of clinical outcomes by the 21-gene test in HR+HER2-breast cancer patients with residual disease after neoadjuvant chemotherapy
    Peg, V.
    de los Angeles, N.
    Vieites, B.
    Bellet, M.
    Castilla, C.
    Gomez Pardo, P.
    Perez-Luque, A.
    Lopez, M. A.
    Salvador Bofill, F. J.
    Alfaro, L.
    Perez Garcia, J. M.
    Espinosa-Bravo, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S171 - S172
  • [9] The Role of Oncotype DX® Recurrence Score in Predicting Axillary Response After Neoadjuvant Chemotherapy in Breast Cancer
    Jaime A. Pardo
    Betty Fan
    Alessandra Mele
    Stephanie Serres
    Monica G. Valero
    Isha Emhoff
    Amulya Alapati
    Ted A. James
    Annals of Surgical Oncology, 2021, 28 : 1320 - 1325
  • [10] Role of Oncotype DX® recurrence score in predicting nodal response after neoadjuvant chemotherapy in breast cancer
    Mele, Alessandra
    Alapati, Amulya
    James, Ted
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 : 172 - 172
12345